A 67-year-old woman was admitted to our hospital for progressive weakness, dysphagia, muscle pain, and weight loss. Here we detail the clinical problem solving involved in diagnosing and treating her immune-mediated necrotizing myopathy caused by anti-HMGCoA reductase autoantibodies. Interestingly, this diagnosis coincided with discovery of a gastrointestinal stromal tumor (GIST) and positivity for anti-nuclear matrix protein (anti-NXP2), another myositis specific autoantibody.
AllenbachYMammenALBenvenisteOStenzelW. Immune-mediated necrotizing myopathies working group. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018;28(1):87–99. doi:10.1016/j.nmd.2017.09.016
2.
YangHLuXPengQ, et al.Differential clinical associations of anti-nuclear matrix protein 2 autoantibodies in patients with idiopathic inflammatory myopathies. Arthritis Rheumatol. 2018;70(8):1288–1297. doi:10.1002/art.40491
MariampillaiKGrangerBAmelinD, et al.Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018;75(12):1528. doi:10.1001/jamaneurol.2018.2598
5.
MammenALChungTChristopher-StineL, et al.Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–721. doi:10.1002/art.30156
6.
AllenbachYArouche-DelapercheLPreusseC, et al.Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement. Neurology. 2018;90(6):e507–e517. doi:10.1212/WNL.0000000000004923
7.
BetteridgeZTansleySShaddickG, et al.Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55. doi:10.1016/j.jaut.2019.04.001
8.
TansleySLLiDBetteridgeZEMcHughNJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology (Oxford). 2020;59(8):2109–2114. doi:10.1093/rheumatology/keaa021
9.
AlbaydaJPinal-FernandezIHuangW, et al.Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(11):1771–1776. doi:10.1002/acr.23188
10.
AllenbachYKeraenJBouvierA-M, et al.High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139(Pt 8):2131–2135. doi:10.1093/brain/aww054
11.
YamaguchiTMatsunagaAIkawaMShirafujiNNishinoIHamanoT. A case of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody-positive paraneoplastic necrotizing myopathy associated with advanced gastric cancer that responded to intravenous immunoglobulin therapy. Clin Neurol. 2017;57(3):118–123. doi:10.5692/clinicalneurol.cn-000982
12.
GrausFDelattreJYAntoineJC, et al.Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–1140. doi:10.1136/jnnp.2003.034447
13.
KassardjianCDLennonVAAlfughamNBMahlerMMiloneM. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015;72(9):996–1003. doi:10.1001/jamaneurol.2015.1207
14.
MammenALTiniakouE. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680–1682. doi:10.1056/NEJMc1506163
15.
MeyerATroyanovYDrouinJ, et al.Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020;22(1):5. doi:10.1186/s13075-019-2093-6
16.
TiniakouEPinal-FernandezILloydTE, et al.More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy. Rheumatol (United Kingdom). 2017;56(5):787–794. doi:10.1093/rheumatology/kew470
